The Nanofacturing consortium has worked on a pan-European nanopharmaceutical project to develop new manufacturing methods and improve supply chain co-ordination to advance treatments for rare cancers, autoimmune diseases and viral infections. The Nanofacturing collaboration has accelerated the development of nanotechnologies with the goal of bringing more targeted and effective therapies to market.
For more information see the IDTechEx report on Biobased Polymers 2018-2023. Specifically, the eight-partner project has centred upon the processing of glycan-coated gold nanoparticles, which have the ability to circulate freely in the blood and, with the addition of targeting ligands, to preferentially enter diseased cells or antigen-processing cells of the immune system.
These small nanoparticles, to which therapeutic drugs or immunotherapeutic peptides can be attached, can pass across blood vessels to deliver medicine directly to diseased sites before being excreted from the body.
Areitio Junquera, Project Co-Ordinator from Midatech Pharma, said:
“This rapidly emerging technology has the potential to deliver drugs more effectively and in a kinder way to patients. Preclinical studies have demonstrated how highly toxic, anti-cancer drugs can be specifically targeted to tumour cells while sparing normal tissue, and how antigenic peptides can be delivered with improved potency to the immune system. Over the course of the project, clinical grade gold nanoparticle treatments have been manufactured and are now being investigated in clinical trials.”
Nanocarriers, which include glycan-coated gold nanoparticles, are forecast to account for 40 per cent of a $136 billion nanotechnology-enabled drug delivery market by 2021(1). However, their development has previously suffered from a number of challenges, with scale-up of production from pre-clinical, laboratory scale to clinical testing hampered by a lack of pilot manufacturing capacity and supply chain infrastructure. High development costs have also prevented SMEs from taking gold nanoparticle drug programs to commercialisation.